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Data Monitoring Committees (DMCs), sometimes
referred to as Data & Safety Monitoring Boards, have
had a successful history over four decades in both gov-
ernment and industry sponsored trials. Their primary
mission is to independently evaluate the accumulating
data in an on-going clinical for the risks and benefits on
behalf of trial participants, investigators, sponsors and
regulators. DMCs can recommend that trials be termi-
nated for overwhelming evidence of benefit, sufficient
evidence of harm, futility or other external information.
This process is quite challenging and requires a multi-
disciplinary team of experts who are independent from
the trial investigators and sponsors.
Despite this long history of success, a number of new
challenges for DMCs have emerged. These include a
serious shortage of trained and experienced experts in
clinical trial monitoring as more trials demand this over-
sight. There is a trend for data monitoring committee
charters to become longer, more complex and appear
similar to a legal document contract that must be
strictly followed when experience indicates this is not
often possible. DMCs are subject to liability risks often
with no indemnification. Restrictions are being placed
on what data can be reviewed and how often as well as
what analyses methods must be used. More recently,
DMCs are being asked to implement certain adaptive
designs which may modify sample size targets based on
emerging trends in a primary outcome despite being
aware that the total data profile might not support such
changes. These along with other challenges will be
discussed.
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